Orchestra BioMed Holdings Inc. (OBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.86 (+1.38%), Market cap $0.24B, 52-week low–high $2.35 ~ $5.35.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeH
Financial statements, price targets, institutional (13F) holdings and related news for Orchestra BioMed Holdings Inc. are updated in real time on BlackAll Trade.
Orchestra BioMed Holdings Inc. trades at $5.86 (+1.38%). Real-time quotes and charts are available on BlackAll Trade.
Orchestra BioMed Holdings Inc. has a market cap of about $0.24B.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy c